ASH: Hematology
<ѻýҕl>OncoBlog: Driving the CAR to a Cancer Cure?ѻýҕl>
Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the "next big thing" in oncology? Presentations and discussion at a recent conference suggest the technology has considerable promise -- but will it qualify as a breakthrough? OncoBlog is a blog by the Medpage Today staff for readers with an interest in oncology. This post comes from Charles Bankhead.
Dec 19, 2013
<ѻýҕl>ASH: Drugs Effective in Chronic ITP Not Appropriate as First-Line Treatmentѻýҕl>
SAN FRANCISCO -- Rituximab (Rituxan) and eltrombopag (Promacta) are "too aggressive and too expensive" for use as first-line therapies against chronic idiopathic thrombocytopenic purpura, agreed participants in an exclusive ѻýҕl roundtable discussion.
Dec 09, 2008